People with diabetes are at increased risk of CVD.

People with CKD are at increased risk of CVD.

Many patients with diabetes also have CKD which further increases their CVD risk.

Early identification of CKD in patients with diabetes is important to ensure both progression of CKD and CV risks are addressed. Furthermore, recent outcome trials demonstrating a slowing in progression of CKD in patients with diabetes will expand treatment options available

This session will give an overview of the emerging pharmacological data in this field.

• Discuss why identification and monitoring for CKD is important for renal and cardio-vascular outcomes in patients with diabetes
• Describe the emerging evidence for improved renal outcomes in the management of patients with diabetes
• Consider the place of pharmacological therapy in the diabetic CKD pathway